A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
Latest Information Update: 25 Nov 2024
At a glance
- Drugs TQB-3702 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 20 Nov 2024 Status changed from not yet recruiting to recruiting.
- 26 Aug 2024 New trial record